Abstracts tagged "ANCA"

Abstract Number: 1751 • 2017 ACR/ARHP Annual Meeting
Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Yuka Iwahashi¹, Aya Kawasaki¹, Fumio Hirano², Ken-ei Sada³, Daisuke Tsukui⁴, Yuya Kondo⁵, Shigeto Kobayashi⁶, Hidehiro Yamada⁷, Hiroshi Furukawa¹, Kenji Nagasaka⁸, Takahiko Sugihara⁹, Kunihiro Yamagata¹⁰, Takayuki Sumida⁵, Shigeto Tohma¹¹, Hajime Kono⁴, Shoichi Ozaki⁷, Seiichi Matsuo¹², Hiroshi Hashimoto¹³, Hirofumi Makino¹⁴, Yoshihiro Arimura¹⁵, Masayoshi Harigai¹⁶ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁶Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁷Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁸Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁰Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹²Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Okayama University Hospital, Okayama, Japan, ¹⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In the epidemiology of ANCA-associated vasculitis (AAV), an obvious difference between European and Asian populations has been reported. According to the clinical classification, granulomatosis…
Abstract Number: 1778 • 2017 ACR/ARHP Annual Meeting
Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Izaya Nakaya¹, Ken-ei Sada², Jun Soma¹, Yoshihiro Arimura³, Masayoshi Harigai⁴, Kunihiro Yamagata⁵, Hirofumi Makino⁶ and Seiichi Matsuo⁷, ¹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ⁴Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁶Okayama University Hospital, Okayama, Japan, ⁷Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Pneumocystis jiroveciipneumonia (PCP) is a fatal complication in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, the current situation of prophylactic treatment of PCP and its…
Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Divi Cornec¹, Brian Kabat¹, John Mills¹, Melissa Cheu², Amber Hummel¹, Darrell Schroeder¹, Matthew Cascino³, Paul Brunetta³, David Murray¹, Melissa Snyder¹, Fernando Fervenza¹, Gary S. Hoffman⁴, Cees G.M. Kallenberg⁵, Carol A. Langford⁶, Peter A. Merkel⁷, Paul A. Monach⁸, Philip Seo⁹, Robert F. Spiera¹⁰, E. William St Clair¹¹, John H. Stone¹², David Barnidge¹ and Ulrich Specks¹³, ¹Mayo Clinic, Rochester, MN, ²Genentech Inc., South San Francisco, CA, ³Genentech, Inc., South San Francisco, CA, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, MN, ⁸Boston University School of Medicine, Boston, MA, ⁹Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Rheumatology, Duke University Medical Center, Durham, NC, ¹²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹³Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…
Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting
Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroder⁵, Brian Kabat⁵, Peter A. Merkel⁶, Carol A. Langford⁷, Gary S. Hoffman⁸, Cees G.M. Kallenberg⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene St. Clair¹², John H. Stone¹³, Ulrich Specks¹⁴ and Paul A. Monach¹⁵, ¹Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, Duke University Medical Center, Durham, NC, ¹³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Boston University School of Medicine, Boston, MA
Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…
Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting
Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Hiromichi Tamaki¹, Robert Butler² and Carol A. Langford³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…
Abstract Number: 1846 • 2017 ACR/ARHP Annual Meeting
Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with granulomatosis with polyangiitis (GPA) are prone to disease relapse. Changes in anti-neutrophil cytoplasmic autoantibodies (ANCA) levels can predict relapses in individual patients…
Abstract Number: 1758 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Xavier Puéchal¹, Christian Pagnoux², Elodie Perrodeau³, Mohamed Hamidou⁴, Jean-Jacques Boffa⁵, Xavier Kyndt⁶, François Lifermann⁷, Thomas Papo⁸, Dominique Merrien⁹, Amar Smail¹⁰, Philippe Delaval¹¹, Catherine Hanrotel-Saliou¹², Bernard Imbert¹³, Chahéra Khouatra¹⁴, Marc Lambert¹⁵, Charles Leské¹⁶, Kim H. Ly¹⁷, Edouard Pertuiset¹⁸, Pascal Roblot¹⁹, Marc Ruivard²⁰, Jean-François Subra²¹, Jean-Francois Viallard²², Benjamin Terrier²³, Pascal Cohen²³, Luc Mouthon²⁴, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group²⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hotel Dieu, Paris, France, ⁴Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁵Paris Tenon, Paris, France, ⁶Valenciennes, Valenciennes, France, ⁷Dax, Dax, France, ⁸Paris Bichat, Paris, France, ⁹Compiègne, Compiègne, France, ¹⁰Amiens, Amiens, France, ¹¹Rennes, Rennes, France, ¹²Brest, Brest, France, ¹³Grenoble, Grenoble, France, ¹⁴Lyon, Lyon, France, ¹⁵Lille, Lille, France, ¹⁶Cholet, Cholet, France, ¹⁷Limoges, Limoges, France, ¹⁸Pontoise, Pontoise, France, ¹⁹Poitiers, Poitiers, France, ²⁰CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ²¹Angers, Angers, France, ²²Bordeaux, Bordeaux, France, ²³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ²⁴Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ²⁵Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Adverse events, rather than active vasculitis, are the greatest threat to patients with ANCA-associated vasculitides (AAVs) during the first year of therapy but long-term…
Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Catherine E. Najem¹, Wenjun Ju², Viji Nair², David Cuthbertson³, Rennie L. Rhee¹, Laura Mariani⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁵, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹, Steven R. Ytterberg¹⁴, Jeffrey Krischer¹⁵, Matthias Kretzler⁴ and Peter A. Merkel¹⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Michigan, Ann Arbor, MI, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Boston University School of Medicine, Boston, MA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵University of South Florida, Tampa, FL, ¹⁶Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…
Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Annalisa Montante¹, Alicia Le Bras², Benjamin Terrier³, Pascal Cohen³, Xavier Puéchal⁴, Alexandre Karras⁵, Philippe Ravaud⁶, Loïc Guillevin⁷ and Isabelle Durand-Zaleski⁸, ¹UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ²UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁵Nephrology, HEGP, Paris, France, ⁶Hôpital Hôtel Dieu, Paris, France, ⁷Internal medicine, Cochin University Hospital, paris, France, ⁸UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
Abstract Number: 2736 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival in Systemic Necrotizing Vasculitides
Sabine Jardel¹, Xavier Puéchal², Alain Le Quellec³, Matthieu Groh², Mohamed Hamidou⁴, Francois Maurier⁵, Olivier Aumaître⁶, Achille Aouba⁷, Thomas Quémeneur⁸, Jean-François Subra⁹, Vincent Cottin¹⁰, Pascal Godmer¹¹, Patrice Cacoub¹², Philippe Delaval¹³, Anne-Laure Fauchais¹⁴, Eric Hachulla¹⁵, Delphine Maucort-Boulch¹⁶, Loïc Guillevin² and Jean-Christophe Lega¹⁷, ¹Lyon 1 University, Lyon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Montpellier, Montpellier, France, ⁴Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁵Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Department of Internal Medicine, Caen University Hospital, Caen, France, ⁸Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁹Angers, Angers, France, ¹⁰Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ¹¹Medecine Interne, CH Vannes, Vannes, France, ¹²Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹³Rennes, Rennes, France, ¹⁴Internal Medicine, Internal Medicine, Limoges, France, ¹⁵CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ¹⁶Biostatistics and bioinformatics, Centre Hospitalier Lyon Sud - Claude Bernard University Lyon 1, Lyon, France, ¹⁷Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France
Background/Purpose: The aim of the study was to describe the evolution of mortality over recent decades in systemic necrotizing vasculitides, including polyarteritis nodosa (PAN), granulomatosis…
Abstract Number: 1762 • 2017 ACR/ARHP Annual Meeting
Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Aya Kawasaki¹, Keita Yamashita², Fumio Hirano³, Ken-ei Sada⁴, Daisuke Tsukui⁵, Yuya Kondo⁶, Yoshitaka Kimura⁵, Kurumi Asako⁵, Shigeto Kobayashi⁷, Hidehiro Yamada⁸, Hiroshi Furukawa¹, Kenji Nagasaka⁹, Takahiko Sugihara¹⁰, Kunihiro Yamagata¹¹, Takayuki Sumida⁶, Shigeto Tohma¹², Hajime Kono⁵, Shoichi Ozaki⁸, Seiichi Matsuo¹³, Hiroshi Hashimoto¹⁴, Hirofumi Makino¹⁵, Yoshihiro Arimura¹⁶, Masayoshi Harigai¹⁷ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Molecular and Genetic Epidemiology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ³Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁵Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁷Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁸Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁹Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹⁰Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹¹Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹³Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁴Juntendo University School of Medicine, Tokyo, Japan, ¹⁵Okayama University Hospital, Okayama, Japan, ¹⁶First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁷Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: ETS Proto-oncogene 1, transcription factor (ETS1) is a transcription factor involved in immune responses. Genome-wide association studies on systemic lupus erythematosus (SLE) in Chinese…
Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting
Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Elodie Perrodeau³, Pascal Cohen², Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Xavier Puéchal²⁰, Philippe Ravaud²¹, Luc Mouthon²² and Loïc Guillevin²⁰, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³Brest, Brest, France, ¹⁴Medecine Interne, CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²¹Hôpital Hôtel Dieu, Paris, France, ²²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…
Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Laure Delaval^1,2, Maxime Samson³, Flora Schein⁴, Christian Agard⁵, Olivier Aumaître⁶, Alban Deroux⁷, Henry Dupuy⁸, Cyril Garrouste⁹, cedric landron¹⁰, Francois Maurier¹¹, Pascal Cathebras¹², Loïc Guillevin^2,13,14 and Benjamin Terrier^15,16,17, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Internal medicine, University Hospital St Etienne, Saint Etienne, France, ⁵Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, CHU de Grenoble, Grenoble, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹²Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹³French Vasculitis Study Group (FVSG), Paris, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁵Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁶French Vasculitis Study Group (FVSG), paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…
Abstract Number: 1763 • 2017 ACR/ARHP Annual Meeting
Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry
Caroline Morbieu, Maher Banjari, Benjamin Terrier, Pascal Cohen, Claire Le Jeunne, Luc Mouthon, Xavier Puéchal and Loïc Guillevin for the French Vasculitis Study Group, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Diagnosing ANCA-associated vasculitides (AAVs) can be challenging. Their clinical presentations are numerous and the time to diagnosis may range from days to years.1,2 The…
Abstract Number: 2935 • 2017 ACR/ARHP Annual Meeting
Nasal Microbiota in Patients with Granulomatosis with Polyangiitis Compared to Healthy Controls
Rennie L. Rhee¹, Antoine G. Sreih¹, Catherine E. Najem¹, Peter C. Grayson², Chunyu Zhao³, Kyle Bittinger³, Ronald G. Collman⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ³Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Medicine & Microbiology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have suggested a potential link between nasal microbes, in particular Staphylococcus aureus, and granulomatosis with polyangiitis (GPA; Wegener’s) but these studies relied…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].